Chimeric Antigen Receptor T Cell

A chimeric antigen receptor T cell (CAR-T cell) is an autologous (patient-derived) or allogeneic (donor-derived) T lymphocyte genetically modified ex vivo via gene therapy to express a synthetic transmembrane Chimeric Antigen Receptor (CAR) that redirects T-cell cytotoxicity against a defined cell-surface antigen on malignant or autoreactive cells. The receptor is termed "chimeric" because it splices together functional protein domains from two distinct branches of adaptive immunology: an extracellular antigen-binding domain derived from the variable regions of a monoclonal antibody (single-chain variable fragment, scFv) and intracellular activation and costimulatory signaling modules derived from the T-cell receptor (CD3ζ) and costimulatory receptors (CD28 or 4-1BB). By combining B-cell-like conformational antigen recognition (Kd ≈ 10−9–10−8 M) with T-cell cytolytic effector potency (perforin/granzyme B) and clonal proliferation, CAR-T cells bypass the requirement for peptide presentation on the major histocompatibility complex (MHC / HLA). Since the first U.S. Food and Drug Administration (FDA) approvals in 2017, CAR-T cellular therapies have produced durable complete remissions in relapsed or refractory B-cell leukemias, lymphomas, and multiple myeloma, establishing a primary modality of advanced immunotherapy in clinical oncology.

Bypassing MHC Restriction and the Two-Signal Requirement

Physiological αβ T-cell receptors (TCRs) recognize only short linear peptides (8–25 amino acids) processed intracellularly by the immunoproteasome and presented inside the groove of host MHC (HLA) molecules (MHC restriction, Zinkernagel and Doherty 1974), and require two concurrent signals:

• Signal 1 (Activation): TCR engagement of peptide–MHC, triggering phosphorylation of Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) on CD3γ, CD3δ, CD3ε, and CD3ζ chains by Lck, recruiting ZAP-70 kinase.
• Signal 2 (Costimulation): Engagement of T-cell CD28 or 4-1BB (CD137) by CD80/CD86 on antigen-presenting cells; Signal 1 without Signal 2 induces T-cell anergy.

Tumor cells frequently evade native TCR surveillance by downregulating MHC Class I or β2-microglobulin (B2M) and lacking CD80/CD86. A synthetic CAR overcomes both mechanisms: its scFv binds intact native cell-surface proteins, glycoproteins, or glycolipids independently of MHC/HLA presentation, while its fused cytoplasmic tail delivers both Signal 1 (CD3ζ) and Signal 2 (CD28 or 4-1BB) upon antigen binding.

Modular Four-Domain Architecture of a CAR

A canonical CAR is a synthetic Type-I transmembrane protein (~50–70 kDa) built from four contiguous modules:

1. Extracellular Antigen-Binding Domain (scFv or VHH Nanobody): Fuses the variable heavy (VH) and light (VL) chains of a monoclonal antibody via a flexible (Gly4Ser)3 linker (such as the murine FMC63 anti-CD19 scFv, or two camelid VHH nanobodies targeting BCMA in ciltacabtagene autoleucel).
2. Extracellular Hinge / Spacer Domain: Derived from CD8α, CD28, or IgG4 stalks; tunes the immunological synapse distance to ~15 nm to exclude the inhibitory phosphatase CD45 from the contact zone.
3. Transmembrane (TM) Domain: An α-helical segment from CD8α or CD28 anchoring the receptor in the plasma membrane.
4. Intracellular Signaling Endodomain: Contains one or two costimulatory modules (CD28 or 4-1BB [CD137]) fused upstream of the CD3ζ (CD247) tail carrying three ITAMs.

---

---

Autologous CAR-T manufacturing spans 10 to 21 days under Current Good Manufacturing Practice (cGMP): (1) Leukapheresis to collect peripheral blood CD3+ T cells; (2) Activation using paramagnetic microbeads coated with anti-CD3/anti-CD28 antibodies plus IL-2 or IL-7/IL-15; (3) Genetic Transduction via viral vector engineering using a self-inactivating (SIN) lentiviral or γ-retroviral vector (or targeted CRISPR-Cas9 knock-in at the TRAC locus on chromosome 14q11.2); (4) Expansion over 6–10 days in a perfusion bioreactor to ~108–109 CAR+ T cells followed by cryopreservation; and (5) 3 days of lymphodepleting conditioning chemotherapy (fludarabine + cyclophosphamide), which depletes endogenous Tregs and cellular "cytokine sinks" to elevate homeostatic IL-7 and IL-15 prior to single-dose CAR-T infusion.

---

1. Cytokine Release Syndrome (CRS) and Neurotoxicity (ICANS)

• Cytokine Release Syndrome (CRS, onset Days 1–14): Proliferating CAR-T cells secrete IFN-γ, GM-CSF, and TNF-α, activating host monocytes, macrophages, and endothelial cells to release Interleukin-6 (IL-6) and Interleukin-1β (IL-1β), causing high fever (≥38.0 °C), capillary leak, hypotension, and hypoxia. First-line treatment is tocilizumab (8 mg/kg IV), a monoclonal antibody blocking membrane-bound and soluble IL-6 receptors (IL-6R), plus corticosteroids or anakinra (IL-1R antagonist).
• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Systemic cytokines and angiopoietin-2 disrupt the blood–brain barrier (BBB), causing aphasia, tremor, dysgraphia (ICE score), seizures, and cerebral edema; treated with CNS-penetrant dexamethasone and anakinra.
• On-Target, Off-Tumor B-Cell Aplasia: Eradication of normal CD19+ B cells and BCMA+ plasma cells causes B-cell aplasia and hypogammaglobulinemia, managed with intravenous immunoglobulin (IVIG).

2. Antigen-Loss Relapse and Solid-Tumor Microenvironment Challenges

Relapse after CD19 CAR-T therapy arises from T-cell exhaustion (PD-1, TIM-3, LAG-3 upregulation driven by TOX and NR4A) or CD19-negative antigen escape via frameshift mutations or alternative splicing skipping of CD19 exon 2 (countered by dual-targeted CD19/CD22 or CD19/CD20 CARs). In solid tumors, efficacy is limited by scarcity of tumor-restricted antigens (addressed by synNotch AND gates or iCAR NOT gates), dense fibrotic stroma blocking T-cell infiltration, antigen heterogeneity, and an immunosuppressive tumor microenvironment (TME) rich in TGF-β, IL-10, PD-L1, adenosine, and Tregs.

---

How does a CAR-T cell recognize and kill cancer cells differently from a normal T cell?

A normal T lymphocyte uses its native αβ T-cell receptor (TCR), which can only recognize fragmented intracellular protein peptides (8–25 amino acids) bound inside the groove of the patient's own Major Histocompatibility Complex (MHC / HLA) molecules, and requires a separate costimulatory signal (CD28–CD80/86) from an antigen-presenting cell. Cancer cells frequently escape native T cells by deleting MHC Class I or β2-microglobulin. A CAR-T cell replaces the TCR binding head with an antibody-derived single-chain variable fragment (scFv) fused directly to intracellular CD28 or 4-1BB costimulatory domains and CD3ζ. This allows the CAR-T cell to bind intact surface proteins (CD19, BCMA), glycolipids (GD2), or glycoproteins on the cancer cell membrane without any MHC presentation, delivering both activation (Signal 1) and costimulation (Signal 2) in a single binding step.

What is the clinical difference between CD28 and 4-1BB costimulatory domains in second-generation CAR-T therapies?

Both CD28 and 4-1BB (CD137) provide the Signal 2 absent from first-generation CARs, but they program T-cell metabolism and differentiation differently. CD28-costimulated CARs (such as axicabtagene ciloleucel and brexucabtagene autoleucel) activate the PI3K–Akt–mTOR pathway, driving aerobic glycolysis, rapid early in vivo proliferation (peaking at Days 7–10), and effector-memory (TEM) differentiation, accompanied by higher rates of early CRS and ICANS and shorter persistence (1–3 months). 4-1BB-costimulated CARs (such as tisagenlecleucel, lisocabtagene maraleucel, and ciltacabtagene autoleucel) signal through TRAF1/2/3 and non-canonical NF-κB, promoting mitochondrial biogenesis, oxidative phosphorylation (fatty-acid oxidation), and central-memory (TCM) differentiation, which produces a more gradual expansion peak, lower rates of high-grade neurotoxicity, and long-term in vivo persistence lasting years.

Why must patients receive lymphodepleting chemotherapy (fludarabine and cyclophosphamide) before CAR-T cell infusion?

If CAR-T cells are infused into a patient with an unconditioned immune system, they show limited expansion and rapid clearance. Administering 3 days of fludarabine and cyclophosphamide (Flu/Cy) prior to infusion remodels the host lymphoid compartment in three ways: (1) it depletes endogenous host lymphocytes that act as "cytokine sinks", causing serum levels of the homeostatic survival cytokines IL-7 and IL-15 to rise 10- to 50-fold to fuel CAR-T proliferation; (2) it eliminates immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) that would otherwise dampen CAR-T cytotoxicity; and (3) it attenuates host immune rejection against the murine or synthetic sequences of the CAR transgene.

---

1. Gross, G., Waks, T., & Eshhar, Z. (1989). "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity." Proceedings of the National Academy of Sciences, 86(24), 10024–10028. https://doi.org/10.1073/pnas.86.24.10024
2. Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002). "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ / CD28 receptor." Nature Biotechnology, 20(1), 70–75. https://doi.org/10.1038/nbt0102-70
3. Maude, S. L., Frey, N., Shaw, P. A., et al. (2014). "Chimeric antigen receptor T cells for sustained remissions in leukemia." New England Journal of Medicine, 371(16), 1507–1517. https://doi.org/10.1056/NEJMoa1407222
4. June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). "CAR T cell immunotherapy for human cancer." Science, 359(6382), 1361–1365. https://doi.org/10.1126/science.aar6711

---